Wordt geladen...
Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin
BACKGROUND: A previous FDA study reported a favorable benefit risk for apixaban compared with warfarin for stroke prevention in older non-valvular atrial fibrillation (NVAF) patients (≥ 65 years). However, it remains unclear whether this favorable benefit risk persists in other populations including...
Bewaard in:
| Gepubliceerd in: | J Gen Intern Med |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer International Publishing
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7728961/ https://ncbi.nlm.nih.gov/pubmed/32989717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11606-020-06180-8 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|